STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months

A Connected Approach to Complex Discovery

Drug discovery moves quickly, and complex biology demands both speed and precision. STORM Therapeutics partnered with Sygnature Discovery to advance their DHX9 inhibitor program with the goal of delivering a best in class pre-clinical development candidate within two years.

Our teams built a fully integrated discovery plan that united chemistry, biology and data driven decision making from day one. Through close collaboration, rapid iteration and diverse hit finding strategies, Sygnature identified multiple unique small molecule hits and advanced the program from lead to pre candidate in just 18 months. This result exceeded typical industry expectations and demonstrated the power of connected discovery.

About STORM Therapeutics

STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME) has led to the discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases.

STORM’s lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1b/2 study in combination with LOQTORZI^®, (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, in patients with NSCLC, HNSCC, melanoma, and endometrial cancer. Further information is available at www.clinicaltrials.gov NCT identifier: NCT06975293.

About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery contract research organization, based in the UK and Canada, with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of close to 900 employees, including 700+ scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature has delivered 61 novel pre-clinical compounds, 38 of which have already progressed to clinical trials. Two have reached major milestones: one has been approved, and another is under regulatory review. Our scientists are named on more than 235 patents and our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.